v3.26.1
Revenue Recognition - Collaboration and License Agreement (Details)
 3 Months Ended 6 Months Ended 67 Months Ended
Nov. 22, 2020
USD ($)
target
program
obligation
Jun. 30, 2026
USD ($)
target
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
target
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
target
Dec. 31, 2025
USD ($)
Nov. 11, 2024
USD ($)
Nov. 30, 2020
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Unsatisfied performance obligation   $ 189,066,000   $ 189,066,000   $ 189,066,000 $ 239,866,000    
Total revenues   $ 58,889,000 $ 54,759,000 $ 117,476,000 $ 114,310,000        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-07-01                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Revenue, remaining performance obligation, expected timing of satisfaction, period   12 months   12 months   12 months      
BMS | Oncology, Neurology, and Immunology Product                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Number of specified biological targets | target 5                
Number of neurology target remaining | target   1   1   1      
Deferred revenue   $ 2,000,000.0   $ 2,000,000.0   $ 2,000,000.0 3,200,000   $ 55,000,000.0
Total milestones to be received from initial programs   482,000,000.0   482,000,000.0   482,000,000.0      
Discovery and development milestones to be received $ 257,000,000.0                
Commercial milestones to be received $ 225,000,000.0                
Deferred revenue, revenue recognized           32,000,000.0      
Number of performance obligations | obligation 1                
Number of programs under agreement | program 5                
Unsatisfied performance obligation $ 55,000,000.0                
Total revenues   500,000 700,000 1,200,000 1,300,000        
Receivable, after allowance for credit loss, current   0   0   0 0    
Novartis Pharma AG | Software contribution | Research, Collaboration and License Agreement                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Deferred revenue               $ 150,000,000.0  
Total milestones to be received from initial programs               2,272,000,000  
Discovery and development milestones to be received               892,000,000.0  
Commercial milestones to be received               $ 1,380,000,000  
Deferred revenue, revenue recognized   0 0 0 0        
Novartis Pharma AG | Software contribution | Collaboration and License Agreement                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Deferred revenue   80,000,000.0   80,000,000.0   80,000,000.0 100,500,000    
Total revenues   8,800,000 $ 7,600,000 20,500,000 $ 13,300,000        
Receivable, after allowance for credit loss, current   $ 0   $ 0   $ 0 $ 0    
Novartis Pharma AG | Software contribution | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-11-12 | Software Agreement                  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]                  
Revenue, remaining performance obligation, expected timing of satisfaction, period               3 years